4/14
08:53 am
ltrn
Lantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22 [Yahoo! Finance]
Low
Report
Lantern Pharma Launches withZeta.ai — the World's First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22 [Yahoo! Finance]
4/14
08:31 am
ltrn
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
Low
Report
Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22
4/9
01:07 pm
ltrn
Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript [Seeking Alpha]
Low
Report
Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript [Seeking Alpha]
4/2
09:08 pm
ltrn
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]
Medium
Report
Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]
4/2
08:10 am
ltrn
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026
High
Report
Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:30 AM Eastern, April 9, 2026
3/30
07:57 pm
ltrn
Lantern Pharma outlines $15B–$20B market potential as AI-driven pipeline advances and funding needs intensify [Seeking Alpha]
High
Report
Lantern Pharma outlines $15B–$20B market potential as AI-driven pipeline advances and funding needs intensify [Seeking Alpha]
3/30
07:57 pm
ltrn
Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript [Seeking Alpha]
High
Report
Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript [Seeking Alpha]
3/30
04:05 pm
ltrn
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
High
Report
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
3/27
07:23 pm
ltrn
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report
Medium
Report
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report
3/27
07:29 am
ltrn
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
High
Report
Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001
3/23
04:30 pm
ltrn
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
Low
Report
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET
3/16
07:08 am
ltrn
RedChip Highlights Public Companies Advancing the Next Phase of AI Adoption at Virtual Investor Conference on March 19 [Yahoo! Finance]
Low
Report
RedChip Highlights Public Companies Advancing the Next Phase of AI Adoption at Virtual Investor Conference on March 19 [Yahoo! Finance]
2/12
11:33 am
ltrn
Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition [Yahoo! Finance]
Low
Report
Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition [Yahoo! Finance]
2/10
08:45 am
ltrn
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
Medium
Report
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026
1/20
08:00 am
ltrn
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
Low
Report
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas